163 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
level, dose of VAFSEO, or dosing strategy that does not increase these risks.
Use the lowest dose of VAFSEO sufficient to reduce the need for red blood … , dose of VAFSEO, or dosing strategy has been identified to avoid these risks. Use the lowest effective dose and adhere to dosing and Hb monitoring
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia
Akebia’s Launch Strategy Developed to Drive Toward a Potential New … with the approved label, Akebia will execute a launch strategy to drive Vafseo toward the goal of becoming a new oral standard of care for adult
8-K
EX-99.1
rmtlvlu1uq 029
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
0c5hvsijt mw
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
EX-99.1
v80on w9se20cxkhy
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
1kiyybx5q0d
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
8-K
EX-99.1
axlxgnjcpp4qvif3
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
8-K
EX-99.1
vv60x1
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
8-K
EX-99.1
ptg6sur86mo
17 Aug 23
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
4:09pm
8-K
8f55kmywnxo7vk2sq6z
17 Aug 23
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
4:09pm
8-K
EX-99.1
372mgsv5ycfz
11 Aug 23
Akebia Therapeutics Provides Update on Form 10-Q Filing
7:35am
8-K
EX-99.1
15zghwv3it63837hhk57
18 Jul 23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
7:47am